---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-24-000062"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:32:14.396211+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q1 2024: XDEMVY sales $24.7M (+89% QoQ), net loss $35.7M, cash $298.5M

## Summary
- Q1 net product sales of XDEMVY $24.7M, up 89% from Q4 2023; ~26,000 bottles delivered (65% increase).
- Net loss of $35.7M ($1.01 loss per share) vs $23.4M loss in Q1 2023.
- SG&A expenses surged to $51.6M from $15.1M due to commercial launch costs.
- Cash and marketable securities $298.5M as of Mar 31; secured $200M credit facility in Apr 2024 (drew $75M).
- Secured commercial payer contracts covering ~18M lives on preferred status; broad coverage expected by end of 2024.

## SEC filing metadata
- accession: 0001819790-24-000062
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000062/0001819790-24-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000062/tars-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-24-000062
- JSON: https://secwatch.observer/filing/0001819790-24-000062.json
- Plain text: https://secwatch.observer/filing/0001819790-24-000062.txt

## Key facts
- Earnings Releases
  Tarsus Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $27.6 million, net income $35.7 million, EPS $(1.01).
  - Period: first quarter ended March 31, 2024
  - Revenue: $27.6 million
  - Net income: $35.7 million
  - EPS: $(1.01)
  - Result: reported results
  source text: million at the close, providing approximately $40 million net after the repayment of the previous facility First Quarter 2024 Financial Results • First quarter revenues were $27.6 million, driven primarily by $24.7 million in net product sales, and $2.9 million in license fees and collaboration revenue. • Cost of sales were $1.7 million, due to manufacturing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979024000062/0001819790-24-000062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.